Use of intravenous amiodarone for postoperative junctional ectopic tachycardia in children

W P Laird1, C S Snyder, N J Kertesz

  • 1Department of Pediatric Cardiology, Texas Children's Hospital, Baylor College of Medicine, 6621 Fannin, Houston, TX 77030, USA.

Pediatric Cardiology
|October 9, 2002
PubMed

Insights

Intravenous amiodarone effectively treats postoperative junctional ectopic tachycardia (JET) in children, improving heart rate and blood pressure. This treatment is safe and recommended for unstable patients failing other therapies.

Area of Science:

  • Pediatric Cardiology
  • Clinical Pharmacology

Background:

  • Postoperative junctional ectopic tachycardia (JET) poses a significant risk in pediatric patients.
  • Conventional therapies may be insufficient for hemodynamically unstable JET cases.

Purpose of the Study:

  • To evaluate the efficacy and safety of intravenous (IV) amiodarone for treating pediatric postoperative JET.
  • To determine optimal dosing and assess outcomes in children with refractory or unstable JET.

Main Methods:

  • Retrospective review of 11 pediatric patients treated with IV amiodarone for JET.
  • Analysis of pre- and post-treatment heart rate, blood pressure, dosage, and duration of therapy.
  • Success defined as reversion to sinus rhythm or stable heart rate.

Main Results:

  • IV amiodarone significantly reduced mean heart rate from 203 bpm to 147 bpm and increased systolic blood pressure from 64 mmHg to 88 mmHg post-load.
  • 9 out of 11 patients achieved sustained JET control.
  • Reported side effects included transient hypotension and sinus bradycardia; long-term oral therapy was rarely needed.

Conclusions:

  • Intravenous amiodarone is a safe and effective treatment for pediatric postoperative JET, particularly in hemodynamically unstable patients or those unresponsive to other treatments.
  • Recommended dosing involves a loading dose followed by an infusion for 48-72 hours.
  • Long-term oral amiodarone therapy is generally not required for postoperative JET.

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Dysrhythmias VII: Nursing Management of Dysrhythmias01:25

Dysrhythmias VII: Nursing Management of Dysrhythmias

Nursing management of dysrhythmias involves the following:AssessmentSubjective Assessment:The initial step involves gathering patient-reported symptoms such as dizziness, palpitations, and chest discomfort. It is crucial to collect a detailed history, including previous heart conditions, current medication use, and lifestyle factors like caffeine and alcohol consumption.Objective Assessment:This involves observing clinical signs such as jugular venous distention, cool and pale skin, and...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...